Bioxytran (OTCMKTS:BIXT – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
Bioxytran Trading Down 15.7%
BIXT opened at $0.02 on Friday. The business’s 50 day moving average is $0.03 and its 200-day moving average is $0.03. The stock has a market cap of $2.41 million, a PE ratio of -1.05 and a beta of 1.98. Bioxytran has a twelve month low of $0.02 and a twelve month high of $0.09.
About Bioxytran
Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.
Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.
Featured Stories
- Five stocks we like better than Bioxytran
- AirJoule Technologies: Short Squeeze Setup Amid Rising Risks
- MarketBeat Week in Review – 08/10 – 08/14
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
